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Emergency Portacaval Shunts" Is Orloff Correct?
ABSTRACT
Orloff, M.J., Bell, Jr., R. H., Orlo, M.S., Hardison,
W.G.M. and Greenburg, A.G. (1994) Prospective
randomized trial of emergency portacaval shunt and
emergency medical therapy in unselected cirrhotic
patients with bleeding varices. Hepatology; 20: 863-
872.
A prospective randomized trial was conducted
in unselected, consecutive pateints with bleed-
ing esophageal varices resulting from cirrhosis
comparing (1) emergency portacaval shunt
performed within 8 hr of initial contact (21
patients) with (2) emergency medical therapy
(intravenous vasopressin and esophageal bal-
loon tamonade) followed in 9 to 30 days by
elective portacaval shunt in survivors (22
patients). All patients underwent the same
diagnostic workup within 3 to 6 hr of initial
contact, and received indentical supportive
therapy initially. All patients were followed
up for atleast 10 hr. The protocol contained no
escape or crossover provisions. There were no
statistically significant differences between the
two treatment groups in the incidence of any of
the clinical variables, results of laboratory tests
or degree of portal hypertension. Child’s risk
classes in the shunt group were A-2 patients, B-
8 patients and C-11 patients, whereas in the
medical group they were A-10 patients, B-5
patients, and C-7 patients, a significant differ-
ence (p<0.01) that might have favored emer-
gency medical treatment. Bleeding was
controlled initially and permanently by emer-
gency shunt in eve.ry patient, but by medical
therapy in only 45% (p<0.001). Mean require-
ment for blood transfusion was 7.1+ 2.6 units
in the shunt group and 21.4+ 2.6 units in the
medical group (p<0.001). Eighty-one percent of
the pateints in the shunt group were dis-
charged alive compared with 45% in the
medical group (p=0.027). Five- and 10-yr ob-
served survival rates were 67% and 57%,
respectively, after emergency shunt compared
with 18% and 18%, respectively, after the
combination of emergency medical therapy
and elective shunt (p<0.01). These survival
rates produced by emergency shunt performed
within 8 hr of initial contact confirm the
effectiveness of this procedure observed in
our previous unrandomized studies. (Hepato-
logy 1994; 20: 863-872.)
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PAPER DISCUSSION
The study by Orloff and associates on the use of
emergency portacaval shunt (EPCS) versus the
combination of emergency medical therapy
(EMT) and a subsequent elective shunt, suggests
a significant benefit to immediate portacaval
shunting for patients with bleeding esophageal
varices and cirrhosis. Both early and long-term
survival rates were significantly greater in the
EPCS group. Bleeding was controlled in only
45% of patients treated with EMT, consisting of
intravenous vasopressin and esophageal balloon
tamponade followed 9 to 30 days later by
elective portacaval shunt; the remaining patients
in this group died from uncontrolled bleeding
during the initial hospitalization. In contrast,
bleeding was controlled in 100% of patients
undergoing EPCS, 81% of whom were dis-
charged alive. Although long-term differences
in survival between the treatment groups are
just as impressive as the early results, multiple
factors other than the initial treatment selected
are likely to have influenced outcomes. The only
important end points that should be considered
in this trial are control of bleeding and survival
during the initial hospitalization.
The authors are to be commended for achiev-
ing results with EPCS which are superior to
those obtained in another recent controlled trial
and in virtually all other uncontrolled series of
EPCS[1]. An early mortality rate of only 19% for
unselected cirrhotic patients (over 50% of whom
were in Child’s class C) with acute variceal
hemorrhage is impressive indeed. How are
Orloff and his associates able to salvage such a
high percentage of desperately ill patients when
so many others have been unable to even
approach these enviable results? Dr. Orloff’s
contention would be that his approach is unique.
No one else has attempted to uniformly accom-
plish surgical portal decompression within 8
hours of admission for all patients who bleed
from varices. He maintains that such early
definitive treatment prevents the hepatic func-
tional deterioration that so often plagues the
hospital courses of patients who persistently
bleed or rebleed. However, in order for such a
therapeutic protocol to be effective, early referral
to an institution with 24-hour availability of a
surgical team with skills and experience com-
mensurate with that of Dr. Orloff’s team is
essential. Such resources are not available in
most areas of the United States and other
countries, especially those regions with a large
rural population, where patients typically make
stops at one or more hospitals before arriving at
an institution capable of successfully providing
definitive treatment for variceal hemorrhage.
Along the way, persistent bleeding frequently
leads to deterioration of hepatic function and a
risky situation for emergency surgery. Such
patients would benefit from initial non-opera-
tive therapy if it were reasonably effective.
Ideally, such therapy would be widely available
including relatively small community hospitals
where these patients often first seek medical care.
Another notable finding of this trial, equal in
importance to the observation that EPCS
salvaged a high percentage of patients, is the
general ineffectiveness of non-operative therapy
compared to other reports[2,3,4]. Only 36% of
bleeding episodes were controlled with the
combination of vasopressin and balloon tampo-
nade. The dismal results in the EMT group with
respect to bleeding control and early survival
likely relate to two factors: 1) ineffectiveness of
the medical treatment options used (vasopressin
and balloon tamponade), and 2) disallowal of
cross-over from the EMT to EPCS group when
EMT failed. Our prinicipal concern with this
study relates to its relevance to current practice,
because endoscopic therapy, which has been
demonstrated in multiple controlled trials to be
superior to vasopressin infusion and balloon
tamponade, was not utilized in the EMT limb.HPB INTERNATIONAL 255
Although not widely availble when this trial was
initiated in 1978, endoscopic treatment (sclerosis
and banding) has become the mainstay in most
centers for management of the acute variceal
bleeder with bleeding control rates in excess of
70% in nearly all series[4,5,6]. Additionally,
other effective non-operative therapies such as
transjugular intrahepatic portosystemic shunt
(TIPS)[7] and intravenous octreotide[4,8] have
been introduced since the completion of this
trial. Since a TIPS accomplishes portal decom-
pression in a manner similar to a surgical shunt,
it would be expected to relieve variceal bleeding
as well, with potentially less morbidity, espe-
cially in high risk patients. Patients treated with
TIPS often improve their liver function, but
those who deteriorate due to inadequate func-
tional hepatic reserve can be considered for liver
transplantation. Unlike patients with surgical
shunts, TIPS does not increase, and in fact may
decrease the risk of liver transplantation.
Since the results of this trial, which enrolled
patients from 1978 to 1983 but which was not
published until 1994, may have limited rele-
vance to the management of acute variceal
bleeding in 1996, the results of an ongoing trial
of EPCS versus endoscopic treatment by Orloff’s
group are eagerly awaited. Will this provide a
definitive answer? Probably not, because TIPS is
now available for high-risk patients who fail
emergency endoscopic treatment. In fact, it is
unlikely that any single therapy will ever be
uniformly applicable to this heterogeneous
group of patients. Now that several effective
modalities are available, a thoughtful, individua-
lized approach is essential to obtain optimal results.
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Prediction of the First Variceal Haemorrhage
ABSTRACT
Siringo, S., Bolondi, L., Gaiani, S., Sofia, S., Zironi,
G., Rigamonti, A., Di Febo, G., Miglioli, M., Cavalli,
G. and Barbara, L. (1994). Timing of the first variceal
hemorrhage in cirrhotic patients: Prospective evalua-256 HPB INTERNATIONAL
tion of doppler flowmetry, endoscopy and clinical
parameters. Hepatology; 20: 66-73.
We followed 87 cirrhotic patients with esopha-
geal varices and without previous hemorrhage
for a mean period of 24 mo to prospectively
evaluate the occurance of variceal bleeding
within (early) or after (late) 6 mo from entry
and the contribution of portal Doppler ultra-
sound parameters to the prediction of early and
late hemorrhage. Clinical, biochemical, endo-
scopic and portal Doppler ultrasound para-
meters were recorded at entry. Variceal
bleeding occurred in 22 patients (25.3%). Nine
(40.9%) bled within the first 6 mo. Cox
regression analysis identified variceal size,
cherry-red spots, serum bilirubin and conges-
tion index of the portal vein (the ratio of portal
vein [cross-sectional area] and portal blood
flow velocity) as the only independent pre-
dictors of first variceal hemorrhage. Discrimi-
nant analysis was used to find the prognostic
index cut off points to identify patients who
bled within 6 mo (prognostic group 1) or after 6
mo (prognostic group 2) or remained free of
bleeding (prognostic group 3). The cumulative
proportion of patients correctly classified was
73% in prognostic group 1, 47% in prognostic
group 2 and more than 80% in prognostic
group 3. The addition of Doppler ultrasound
flowmetry to clinical, biochemical and endo-
scopic parameter only improved the classifica-
tion of patients with early bleeding.
(Hepatology 1994; 20: 66-73.)
Keywords: Variceal haemorrhage cirrhosis portal
hypertension, oesophageal varices
PAPER DISCUSSION
Approximately, 25 to 30% of cirrhotic patients
with esophageal varices and without previous
variceal hemorrhage will bleed from ruptured
varices and 70% of them will do so within the
first two years of follow-up [1]. However,
studies evaluating the risk factors for the first
variceal bleeding have not assessed the timing of
the variceal bleeding during this period [2-4].
The assessment of these patients suggest [5] that
the risk of bleeding within the first two years is
not constant; it tends to decrease after an inital
period of six months. Therefore, the identifica-
tion of risk factors for early and late bleeding is
important because it could allow randomization
of patients into different treatment groups in
prophylactic trial for the prevention of a first
variceal hemorrhage, i.e. by betablockers or
endoscopic sclerotherapy.
Risk factors for a high bleeding risk have been
described by our group [6], by the Japanese
Research Society for Portal Hypertenion[7] and
by the North Italian Endoscopy Club[2]. How-
ever, in these description the role of portal
hemodynamics in the prediction of variceal
bleeding are not included. The New Haven
Group [8] has described the prevalence of a
certain level of portal pressure for the risk of
variceal bleeding. Therefore, this additional risk
factor was included in a prospective rando-
mized trial of prophylactic endoscopic sclero-
therapy of our group and seems to be very
useful [9].
However, this selection criterion is invasive
and thus has limits. Doppler ultrasound is a new
tool for evaluating portal hypertension, provid-
ing a non invasive assessment of blood flow in
most splanchnic vessels. The current use of
doppler ultrasound has focused on studies of
pathophysiology of portal hypertention and on
assessment of effects of vasoactive drugs on
splanchnic blood flow. Early studies of portal
hemodynamics in cirrhotic patients may have a
potential prognostic value in assessment of the
risk of variceal bleeding [12].
Therefore, the group of Siringo prospectively
evaluated the (a) occurrence of the first variceal
bleeding, defined hemorrhage occurring within
six months of entry into control studies, and lateHPB INTERNATIONAL 257
first variceal bleeding (i.e. bleeding occuring
after six months of follow-up), and (b) the role of
portal doppler ultrasound parameters, in addi-
tion to clinical and endoscopic criteria, in
predicting the early and late occurrence of
hemorrhage, as well as the possibility of patients
remaining free of bleeding.
Therefore, during the period of 38 months, 95
consecutive cirrhotic patients with esophageal
varices and without previous variceal hemor-
rhage were subjected to doppler ultrasound
evaluation. The doppler ultrasound was techni-
cal feasible in 87 patients (91,6%), who were
subseqently followed up for a mean period of
24,0 (4-14,5) months. 71 (81.6%) of the 87 were
inpatients when they entered the study. At
entry, the patients underwent upper gastroin-
testinal endoscopy, and varices were classified
according to the Japanese Research Society of
portal hypertension endoscopic rule [7]. Clinical
and biochemical data were recorded in each
patient, and the severity of the liver disease was
assessed using the Cambell numeral modifica-
tion of Child’s grading[13].
The following portal hemodynamic para-
meters were evaluated in the 87 patients by
means of real-time ultrasound equipment with a
3,5-MHz-convex transducer with a pulse dop-
pler device working at 3,5 and 2,5 MHz
frequencies:
a) Diameter of the portal vein (PV) (mm) was
calculated as the anteroposterior diameter dur-
ing suspended respiration at the largest point.
b) Blood flow velocity of the portal vein (PV)
(cm/min.) was calculated with the equipment
from the doppler spectrum described by
Gill[14]. The mean velocity (Vmean) of portal
flOW was measured. The sample volume, as
large as at least half of the vessels caliber was
positioned lcm distal to the crossing point of the
hepatic artery with the portal trunk in an
oblique, subcostal scan.
c) Portal blood flow volume (PFV) (mm/min.)
was calculated by the formula FVF=Vmean r .2
where r represents the diameter of the vessel.
d) Congestion index of the portal vein (CI):
ratio of cross-sectional area and the blood flow
velocity in the portal vein. The CI was calculated
according to a modified Moriyasus’s formula
(15) using the Vmean instead of the maximal flow
velocity.
CI (r)2 "r/10
Wmean
where r is the vessels radius. For example, a
portal vein diameter of 16mm and a portal flow
velocity of 12 cm/min, yields a CI of 1.67.
In additon, the group of Siringo searched for
spontaneous portal-systemic shunts and portal
vein thrombosis in all patients. These two
variables were referred to as morphological
ultrasonographic findings.
The diagnosis of variceal hemorrhage was
made when after an episode of hematemesis,
melena or both emergency endoscopy (within 72
hours of the clinical manifestation of bleeding or
index bleed), showed (a) active bleeding, a clot
or a "white nipple" on a varix; (b) no lesions
potentially responsible for bleeding when
varices lacked the previously described signs;
or (c) potential sources of hemorrhage other than
varices but without signs of active or recent
bleeding. Patients who did not undergo emer-
gency endoscopy were considered to have bled
from an unknown source. In this case the varices
were considered the source of bleeding.
Thereafter, an univariate and multivariate
analysis and a development of a prognostic
model was performed including the mentioned
risk factors. In this discriminant analysis the
prognostic index, cut off points were found to
identify patients who bled within 6 months
(prognostic group I), after 6 six months (prog-
nostic group II) or remained free of bleeding
(prognostic group III). The cumulative propor-
tion of patients correctly classified was 73% in
the prognostic group I, 47% in the prognostic
group II, and more than 80% in the prognostic
group III. The addition of doppler ultrasound258 HPB INTERNATIONAL
flowmetry to clinical, biochemical and endo-
scopic parameters only improves the classifica-
tion of patients with early bleeding.
Thus, the cumulative rate of bleeding within 6
months in the group with early bleeding, as
predicted by clinical and endoscopic criteria,
was only 54%, quite poor and similar to 58%, as
predicted by the North Italian Endoscopy Index
of more than 40%[2]. The cumulative rate of
actual bleeding predicted in this group was
significantly improved (19% more) by the Con-
gestion Index. However, the identification of
patients with late occurrence of bleeding (after 6
months from entry) was poor in both models,
with or without the inclusion of the Congestion
Index (45 vs. 50%).
In conclusion, the study of Siringo et al.[5]
shows, that a subgroup of cirrhotic patients is at
a high risk of bleeding within 6 months of entry
into the study. This subgroup of patients is best
identified by a prognostic model based on
clinical, endoscopic and doppler parameters.
Patients who bled after 6 months from entry
are poorly identifiable when only the status at
entry is analyzed. Thus in this group the Con-
gestion Index only poorly improved the bleed-
ing risk criteria introduced by the North Italian
Endoscopy Club (2). However, the criteria
described by our group[9] are more reliable.
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Liver and Pancreatic Resection in the Elderly
ABSTRACT
Fong, Y., Blumgart, L.H., Fortner, J.G and
Brennan, M.F (1995). Pancreatic or liver resection
for malignancy is safe and effective for the elderly.
Annals of Surgery, 222: 426-437.
Background: Liver resection, or pancreatico-
duodenectomy, has traditionally been thought
to have a high morbidity and. mortality rate
among the elderly. Recent improvements in
surgical and anesthetic techniques, an increas-
ing number of elderly patients, and an increas-
ing need to justify use of limited health care
resources prompted an assessment of recent
surgical outcomes.
Methods: Five hundred seventy-seven liver re-
sections (July 1985-July 1994) performed for
metastatic colorectal cancer and 488 pancreatic
resections (October 1983-July 1994) performed
for pancreatic malignancies were identified in
departmental data bases. Outcomes of patients
younger than age 70 years were compared with
those of patients age 70 years or older.
Results: Liver resection for 128 patients age 70
years or older resulted in a 4% perioperative.
mortality rate and a 42% complication rate.
Median hospital staywas 13 days, and 8% of the
patientsrequired admission to the intensive care
unit (ICU). Median survivalwas 40 months, and
the 5-year survival rate was 35%. No difference
were found between results for the elderly and
those for younger patients who had undergone
liver resection, except for a minimally shorter
hospital stayfortheyoungerpatients (median,12
days vs. 13 days p=0.003). Pancreatic resection
for 138 elderly patients resulted in a mortality
rate of 6% and a complication rate of 45%.
Median stay was 20 days, and 19% of the
patients required ICU admission, results iden-
tical to those for the younger cohort. Long-term
survival was poorer for the elderly patients,
with a 5-year survival rate of 21% compared
with 29% for the younger cohort (p=0.03).
Conclusions: Major liver or pancreatic resec-
tions can be performed for the elderly with
acceptable morbidity and mortality rates and
possible long-term survival. Chronologic age
alone is not a contraindication to liver or
pancreatic resection for malignancy.
Keywords: Liver resection, hepatic resection,
pancreatic resection, elderly
major surgery
PAPER DISCUSION
In recent years, advances in surgical practice
have seen a reduction in morbidity and mortal-
ity rates for major hepatobiliary and pancreatic
resectional surgery. Given that surgical resection
is the only potential curative therapy for
malignant disease of the liver and pancreas,
many surgeons have advocated a more aggres-
sive approach to the management of such
malignancy in the anticipation of demonstrating
improved long-term survival. Whilst the title of
this paper from the Memorial Sloan-Kettering
Cancer Center might support a relaxation of
previously stringent selection criteria, the results
require close scrutiny before other surgeons rush
to follow suit and increase their own resectional
practice.
In the management of pancreatic cancer,
several recent series testify to the fact that
pancreaticoduodenectomy can be undertaken
with minimal mortality and low morbidity rates
[1, 2]. The authors report a creditable6% mortality
rate amongst the 138 patients over the age of 70
years undergoing pancreatic resection. The ope-
rative mortality rate was little different than for260 HPB INTERNATIONAL
those patients less than 70 years of age under-
going similar resections. Five year survival was
21%, although none of the 10 patients surviving to
five years underwent resection for pancreatic
adenocarcinoma. The careful selection of patients
for considerationofresection isexemplifiedbythe
fact that only 69 of the 138 patients undergoing
pancreatic resection had pancreatic adenocar-
cinoma. The intense demands placed on
hospital resource with such surgery is high-
lighted by the 45% complication rate and the
19% intensive care admission rate, although
median hospital stay was 20 days. There are no
data available to indicate whether recovery and
return to normal activity was different in
patients over 70 years of age and, as in
similarly reported series, there is no assessment
of the quality of life in patients following
discharge.
The authors do recognise the potential effect
of the pre-referral selection process in contribut-
ing to their good results. Further, it is noted that
the authors have adopted the use of laparoscopy
as a means of avoiding unnecessary laparotomy
[3]. Our own experience suggests that a
combination of laparoscopy and laparoscopic
ultrasonography will avoid unnecessary non-
therapeutic laparotomy [4], the morbidity of
which is not often appreciated from the publica-
tion of selected patients undergoing resectional
surgery. The median survival of 18 months
following pancreatic resection reported by the
authors merely serves to underline the impor-
tance of selecting out patients unlikely to benefit
from an aggressive surgical approach.
A more encouraging role for hepatic resection
in the management of colorectal metastases is
evident from a number of studies which have
demonstrated five year survival rates of up to
40% [5,6]. The present paper reports an encoura-
ging 35% five year survival rate which is not
dissimilar to the 39% five year survival rate
observed in patients under the age of 70 years.
Forty two percent of patients developed post-
operative complications and there was a 4%
peri-operative mortality rate. Male patients had
a greater risk for complication than female
patients and perhaps not surprisingly resection
of at least one lobe of the liver and operative
times exceeding four hours were associated
with increased risk. It is unfortunate that such
important factors of post-operative outcome
may not therefore be easily predicted before
patients are submitted to laparotomy. It is not
readily evident from other reported series as to
whether patients with other forms of hepatic
malignancy can be similarly considered for
resectional surgery with advancing years. Ope-
rative mortality rates as high as 41% have been
reported over the last ten years for patients
undergoing resection for primary hepatic ma-
lignancy [7, 8, 9].
It is evident that the authors are indeed able
to conclude that "patients with pancreatic or
liver malignancy should be considered for
surgical therapy regardless of chronologic
age". Nonetheless, it is apparent that assessment
of individual risk for patients undergoing resec-
tional surgery is not always possible. Relaxation
of existing criteria for considering patients for
complex hepatobiliary and pancreatic resection
should therefore only be undertaken in estab-
lished centres with a proven track record in this
specialist field of surgery.
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Pre-Liver Transplant: Tips Versus
Shunt
Distal Splenorenal
ABSTRACT
Abouljoud, M.S., Levy, M.F., Rees, C.R., Diamond,
N.G., Lee, S.P., Mulligan, D.C., Goldstein, R.M.,
Husberg, B., Gonwa, T.A. and Klintmalm, G.B.
(1995)A comparison of treatment with transjugular
intrahepatic portosystemic shunt or distal splenor-
enal shunt in the management of variceal bleeding
prior to liver transplantation. Transplantation, 59:
226-229.
Recurrent variceal bleeding in liver transplant
candidates with end-stage liver disease can
complicate or even prohibit a subsequent
transplant procedure (OLT). Endoscopic
sclero-therapy and medical therapy are consi-
dered as first-line management with surgical
shunts reserved for refractory situations. Surgi-
cal shunts can be associated with a high
mortality in this population and may compli-
cate subsequent OLT. The transjugular intra-
hepatic portosystemic shunt (TIPS) has been
recommended in these patients as a bridge to
OLT. This is a new modality that has not been
compared with previously established thera-
pies such as the distal splenorenal shunt
(DSRS). In this study we report our experience
with 35 liver transplant recipients who had a
previous TIPS (18 patients) or DSRS (17
patients) for variceal bleeding. The TIPS group
had a significantly larger proportion of criti-
cally ill and Child-Pugh C patients. Mean
operating time was more prolonged in the
DSRS group (P=0.014) but transfusion require-
ments were similar. Intraoperative portal vein
blood flow measurements averaged 2132+/-725
ml/min in the TIPS group compared with
1120+/-351ml/min in the DSRS group (P<0.001).
Arterial flows were similar. Mean ICU and
hospital stays were similar. There were 3
hospital mortalities in the DSRS group and
none in the TIPS group (P=0.1). We conclude
that TIPS is a valuable tool in the management
of recurrent variceal bleeding prior to liver
transplantation. Intra0Perative hemodynamic
measurements suggest a theoretical advantage
with TIPS. In a group of patients with advanced
liver disease we report an outcome that is
similar to patients treated with DSRS prior to
liver transplantation. The role of TIPS in the
treatment of nontransplant candidates remains
to be clarified.262 HPB INTERNATIONAL
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PAPER DISCUSSION
The paper by Abouljoud, et al. describes their
experience with the use of transjugular intrahe-
patic portosystemic shunt (TIPS) in a busy
transplant service and compares distal spleno-
renal shunts (DSRS) to TIPS relative to post-
transplant outcome. Variceal bleeding in patients
with portal hypertension is a frequent finding in
patients with end stage liver disease[I-4]. It is
critically important to assess risk factors for
bleeding and to use preventive strategies in the
evaluation and management of patients with
known varices in the patient awaiting transplan-
tation since variceal bleeding may exclude or
complicate liver transplantation. Therapeutic
options for treatment ofbleeding esophagogastric
varices and prevention of rebleeding should be
structured to optimize patient outcome and
assure successful transplantation.
Risk factors for predicting hemorrhage from
varices have been well defined. Variceal size,
intravariceal pressure, red color signs and the
Child Pugh classification of liver disease are
important variables in the evaluation of patients
at risk for hemorrhage[5]. Lebrec et al. have
shown that a portal or hepatic venous pressure
gradient of at least 12 mm Hg is required for the
developement of hemorrhage from esophageal
varices, but that gradations in pressure above 12
mm Hg are not associated with a proportional
increase in bleeding risk [6].
Prevention of variceal bleeding is important
because mortality dramatically increases after
bleeding occurs. Non-selective beta blockers may
beused to prevent the first varicealhemorrhage in
patients with end stage liver disease; patients
with decompensated liver disease andmedium to
large varices are most likely to benefit[7,8].
Prevention of initial variceal hemorrhage through
shunt surgery is not beneficial. Prophylatic
sclerotherapy of varices is also not an effective
preventive strategy [8,9]. Patients with end stage
liver disease who bleed from esophageal varices
warrant aggressive treatment to control the initial
bleed and to prevent rebleeding. Acute bleeding
may be controlled endoscopically with either
sclerotherapy or band ligation[2-4,10]. Endo-
scopic ligation of varices controls acute bleeding
as effectively as sclerotherapy, but with fewer
complications, reduced rebleeding rates, and
possibly improved survival [10]. Well-known
complications associated with endoscopic treat-
ment include esophageal ulceration or perfora-
tion, cardiopulmonary sequelae, and infections,
all of which may preclude transplantation or
increase operative risk [10-12]. Additionally, va-
soactive agents may be used for the aute
treatment of bleeding varices [13]. Vasopressin
with nitroglycerin, glypressin, somatostatin, and
octreotide may effectively control variceal he-
morrhage, but only glypressin has been shown to
significantly improve survival. In the patientwho
has recovered from a variceal bleed, the addition
of non-selective beta blockers to endoscopic
therapy reduces rebleeding rates when compared
to either therapy alone but mortality rates may
not be significantly improved [14,15].
What options are available for patients who
continue to experience variceal bleeding despite
sclerotherapy, variceal ligation and pharmaco-
logic intervention? Both DSRS and TIPS control
variceal hemorrhage and prevent rebleeding in
over 90% of cases. As with all therapies, risks
and benefits must be carefully considered.
Rebleeding rates and patient survival are not
significantly different between selective and
non-selective shunts but the incidence of hepatic
encephalopathy may be less in patients receiving
DSRS [16-181.
TIPS controls acute variceal bleeding and pre-
vents rebleeding in patients refractory to stan-
dard medical and endoscopic therapy.[19-22]
TIPS has been associated with a variety of
complications [20-22]. Fifteen to 66% of patients
may develop shunt stenosis or occlusion andHPB INTERNATIONAL 263
recurrent variceal bleeding within I year follow-
ing TIPS placement. Seven to 30% of patients may
experience new or worsening encephalopathy. In
addition, improperly placed TIPS may also
increase the difficulty of the transplant opera-
tion [23]. Potential complications resulting from
TIPS should be carefully considered, keeping in
mind the effect that complications may have on
candidacy for liver transplant. TIPS is a short-
term solution for the prevention of recurrent
hemorrhage in patients with end stage liver
disease who are candidates for transplantation.
What factors are important to consider in
management of the potential transplant candi-
date with variceal hemorrhage? Several factors
including the clinical status of the patient, the
etiology and severity of liver disease, and
candidacy for liver transplantation should be
assessed before shunting or placement of TIPS.
The etiology of liver disease influences survival
of the patient with variceal bleeding. Patients
with cholestatic liver disease tolerate variceal
bleeding better than those with parenchymal
liver disease [24,25]. Severity of liver disease is
important in determining whether to use DSRS
or TIPS. Survival in patients with compensated
liver disease receiving DSRS for variceal bleed-
ing is superior to that of patients with decom-
pensated liver disease [26]. Survival in patients
who are treated with DSRS in the setting of
mild to moderate liver disease is comparable to
that of patients receiving allografts for a similar
degree of liver failure, but patients with decom-
pensated liver disease benefit more from trans-
plantation[27,28]. Surgical shunting should be
reserved for patients with compensated liver
disease and hemorrhage refractory to nonsur-
gical methods. TIPS followed by timely trans-
plantation should be considered for patients
with refractory variceal bleeding in the setting
of decompensated liver disease [19,20].
While transplantation is an effective therapy
for end-stage liver disease; management of
variceal hemorrhage needs to be carefully
individualized to optimize patient outcome after
transplantation. Abouljoud et al. describe their
data comparing TIPS and DSRS in regards to
safety, efficacy, long-term complications and
influence on subsequent liver transplantation.
Outcome parameters included operating time,
number of transfusions, intraoperative portal
venous and hepatic arterial flow measurements;
length of stay and operative mortality was also
assessed. Mean operating time was significantly
longer in the DSRS group but there, was no
significant difference in transfusion require-
ments or cold ischemia times between the
groups. Portal venous flow was significantly
reduced in patients receiving DSRS compared to
patients receiving TIPS but there was no
significant difference in hepatic arterial flow
between the groups. Analysis of the data
demonstrated that patients undergoing TIPS
has a similar post-operative course in terms of
mortality, ICU and hospital stay compared to
those patients who had DSRS even though they
had significantly worse liver disease. Although
not statistically significant, it is worth noting that
3 deaths occurred in the DSRS population and
no deaths occurred in the TIPS group. The
authors conclude that TIPS is a valuable tool in
the management of patients with severe end
stage liver disease awaiting transplantation who
present with variceal hemorrhage.
A number of questions regarding methodo-
logy are raised in reviewing the paper by
Abouljoud and colleagues that if clarified
would be helpful in further defining the role
of DSRS vs TIPS as adjunctive therapy in the
potential transplant patient. The definition of
refractory variceal hemorrhage was not pro-
vided. The authors state that follow-up ranged
from 1-96 months. It would be helpful to
know the duration of follow-up prior to and
after liver transplantation. Recent studies sug-
gest that 30 day post-TIPS survival in the non-
transplant candidate with Child-Pugh class C
liver disease and variceal bleeding is consider-
ably worse when compared to that in patients
with milder liver disease [29,30]. TIPSfollowed264 HPB INTERNATIONAL
by timely transplantation in this patient popu-
lation reduces mortality rates; this may account
for the promising results in patients with
Child-Pugh class C liver disease receiving TIPS.
What practical conclusions can we draw from
Abjoulboud’s experience? Their data would
suggest that the use of TIPS can safely serve as
a bridge to transplantation and is particularly
useful in the patient with advanced liver disease.
Although the numbers were too small to draw
firm statistical conclusions, there were three
hospital mortalities in the DSRS group and none
in the TIPS group even though there was a larger
proportion of critically ill and Child-Pugh class
C patients in the TIPS group. However, the role
of DSRS in the treatment of variceal hemorrhage
should not be minimized. In the patient with
relatively well preserved synthetic function and
recurrent variceal hemorrhage, DSRS is a time-
tested, proven and effective treatment. The
application of a less-invasive treatment modality
in the hemorrhaging liver patient adds another
alternative to our arsenal of therapeutic options.
As is the case in all studies of new treatment
modalities, the study suffers from small num-
bers in each group. While the results of
Abouljoud and colleagues are encouraging a
larger, prospective, randomized, controlled trial
comparing endpoints of efficacy and safety of
DSRS and TIPS would be helpful in defining
standards of practice in the patient awaiting
transplantation.
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Is Hepatectomy Necessary in Dealing with Left
Hepatolithiasis with Intrahepatic Duct Stricture?
ABSTRACT
Sheen-Chen, S-M., Cheng, Y-F., Chou, F-F. and Lee,
T-Y. (1995). Ductal dilatation and stenting make
routine hepatectomy unnecessary for left hepato-
lithiasis with intrahepatic biliary stricture. Surgery;
117: 32-36.
Background: Hepatolithiasis with intrahepatic
biliary strictures, more common in Southeast
Asia than elsewhere, remains a difficult pro-
blem to manage. Hepatic resection has recently
been advocated as one of the treatment mod-
alities for hepatolithiasis; however, this proce-
dure is not without risk. This study was
designed to achieve complete clearance of the
stones, eliminate bile stasis, and avoid the
potential risks of hepatic resection in the
patient with hepatolithiasis and intrahepatic
biliary stricture.
Methods: In this prospective clinical trial 13
patients with retained left hepatolithiasis and
intrahepatic biliary strictures were included.
All the patients met the following criteria: (1)
initial surgical procedure for hepatolithiasis,
(2) normal gross findings of the left liver, and